Altimmune, Inc. (NASDAQ:ALT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have received an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $20.83.

Several analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Altimmune in a research report on Tuesday, March 18th. William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Finally, Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price target on the stock.

Insider Buying and Selling at Altimmune

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently modified their holdings of the company. Bellevue Group AG increased its holdings in Altimmune by 43.9% in the 3rd quarter. Bellevue Group AG now owns 863,660 shares of the company’s stock worth $5,303,000 after buying an additional 263,660 shares during the period. Virtu Financial LLC acquired a new stake in shares of Altimmune in the third quarter worth $674,000. Barclays PLC increased its stake in shares of Altimmune by 93.0% in the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after acquiring an additional 75,064 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares during the last quarter. Finally, Stifel Financial Corp lifted its position in Altimmune by 77.4% during the third quarter. Stifel Financial Corp now owns 17,752 shares of the company’s stock valued at $109,000 after purchasing an additional 7,746 shares during the period. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Stock Performance

NASDAQ ALT opened at $5.57 on Friday. The company has a market cap of $428.97 million, a PE ratio of -3.59 and a beta of 0.87. The firm’s 50 day moving average price is $6.27 and its 200-day moving average price is $7.06. Altimmune has a 52-week low of $5.14 and a 52-week high of $11.16.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. On average, analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.